Science Explorer Back to mapMap
Discussion
Topic · Pharmacological Receptor Mechanisms and Effects

Most cited papers in Pharmacological Receptor Mechanisms and Effects

Pharmacological Receptor Mechanisms and Effects

What are the most cited papers in Pharmacological Receptor Mechanisms and Effects?

The most cited paper in Pharmacological Receptor Mechanisms and Effects is "Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China" (Chaomin Wu et al., 2020), with 8,770 citations. Next come "Remdesivir for the Treatment of Covid-19 — Final Report" (7,759) and "Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China" (7,427).

Showing 50 of 98 papers. Every paper with more than 792 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China Chaomin Wu et al. · JAMA Internal Medicine Open access 13 Mar 2020 8,770
2 Remdesivir for the Treatment of Covid-19 — Final Report John H. Beigel et al. · New England Journal of Medicine Open access 22 May 2020 7,759
3 Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China Ling Mao, Huijuan Jin, Mengdie Wang et al. · JAMA Neurology Open access 10 Apr 2020 7,427
4 Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. G. Di Chiara, Assunta Impérato · Proceedings of the National Academy of Sciences Open access Jul 1988 4,770
5 Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Tao Chen et al. · BMJ Open access 26 Mar 2020 4,166
6 Receptors for Purines and Pyrimidines Geoffrey Burnstock, Alexei Verkhratsky Book chapter 2012 3,980
7 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Yeming Wang et al. · The Lancet Open access 29 Apr 2020 3,665
8 Compassionate Use of Remdesivir for Patients with Severe Covid-19 Jonathan D. Grein et al. · New England Journal of Medicine Open access 10 Apr 2020 2,914
9 In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Xueting Yao, Fei Ye, Miao Zhang et al. · Clinical Infectious Diseases Open access 6 Mar 2020 2,780
10 Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis Stefan Leucht, Andrea Cipriani, Loukia Maria Spineli et al. · The Lancet 26 Jun 2013 2,569
11 Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic Jonathan P. Rogers, Edward Chesney, Dominic Oliver et al. · The Lancet Psychiatry ReviewOpen access 18 May 2020 2,521
12 Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) James M. Sanders, Marguerite L. Monogue, Tomasz Z. Jodlowski et al. · JAMA 13 Apr 2020 2,468
13 Opiate Receptor: Demonstration in Nervous Tissue Candace B. Pert, Solomon H. Snyder · Science 9 Mar 1973 2,386
14 Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Xiaochen Li, Shuyun Xu, Muqing Yu et al. · Journal of Allergy and Clinical Immunology Open access 12 Apr 2020 2,378
15 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records Maxime Taquet, John Geddes, Masud Husain et al. · The Lancet Psychiatry Open access 6 Apr 2021 2,279
16 The Excitatory Amino Acid Receptors: Their Classes, Pharmacology, and Distinct Properties in the Function of the Central Nervous System Daniel T. Monaghan, Richard J. Bridges, Carl W. Cotman · The Annual Review of Pharmacology and Toxicology Apr 1989 2,202
17 2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain Takayuki Sugiura, Shigeru Kondo, Akihiro Sukagawa et al. · Biochemical and Biophysical Research Communications Open access Oct 1995 2,199
18 Intrathecal morphine in mice: A new technique Janice L.K. Hylden, George L. Wilcox · European Journal of Pharmacology Oct 1980 1,951
19 Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Stefan Leucht, Caroline Corves, Dieter Arbter et al. · The Lancet Review 7 Dec 2008 1,936
20 Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor Jean‐Claude Meunier, Catherine Mollereau, Lawrence Toll et al. · Nature 12 Oct 1995 1,919
21 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Martin J. Vincent, Éric Bergeron, Suzanne Benjannet et al. · Virology Journal Open access 22 Aug 2005 1,890
22 Potential Effects of Coronaviruses on the Cardiovascular System Mohammad Madjid, Payam Safavi‐Naeini, Scott David Solomon et al. · JAMA Cardiology 27 Mar 2020 1,881
23 Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival Teruo Hayashi, Tsung‐Ping Su · Cell Open access Nov 2007 1,825
24 The Role and Regulation of Adenosine in the Central Nervous System Thomas V. Dunwiddie, Susan A. Masino · Annual Review of Neuroscience Review Mar 2001 1,646
25 β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression Jeffrey D. Rothstein, Sarjubhai A. Patel, Melissa R. Regan et al. · Nature 2005 1,525
26 Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA Maxime Taquet, Sierra Luciano, John Geddes et al. · The Lancet Psychiatry Open access 9 Nov 2020 1,512
27 Benzodiazepine receptors in rat brain Richard F. Squires, Claus Bræstrup · Nature Apr 1977 1,453
28 Adenosine receptors as therapeutic targets Kenneth A. Jacobson, Zhan‐Guo Gao · Nature Reviews Drug Discovery ReviewOpen access Mar 2006 1,430
29 Crystal structure of the µ-opioid receptor bound to a morphinan antagonist Aashish Manglik, Andrew C. Kruse, Tong Sun Kobilka et al. · Nature Open access 20 Mar 2012 1,382
30 ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE ACCUMULATION OF CYCLIC AMP IN CULTURED BRAIN CELLS Dietrich van Calker, Margarete Müller, Bernd Hamprecht · Journal of Neurochemistry Nov 1979 1,373
31 Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study Aravinthan Varatharaj et al. · The Lancet Psychiatry Open access115 authors 25 Jun 2020 1,318
32 International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update Bertil B. Fredholm, Adriaan P. IJzerman, Kenneth A. Jacobson et al. · Pharmacological Reviews Open access 15 Feb 2011 1,316
33 Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients Robert Gottlieb et al. · New England Journal of Medicine Open access 22 Dec 2021 1,288
34 International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy Maria P. Abbracchio, Geoffrey Burnstock, Jean‐Marie Boeynaems et al. · Pharmacological Reviews Open access Sep 2006 1,284
35 Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19 Christoph D. Spinner et al. · JAMA Open access 21 Aug 2020 1,283
36 Pharmacologically induced selective degeneration of chemosensitive primary sensory neurones Gábor Jancsó, Elisabeth Király, Aurelia Jancsó‐Gábor · Nature Dec 1977 1,283
37 Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up Lang Wang, Wenbo He, Xiaomei Yu et al. · Journal of Infection Open access 30 Mar 2020 1,279
38 Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain Robert M. Schwarcz, William O. Whetsell, Richard M. Mangano · Science 21 Jan 1983 1,275
39 Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs John W. Olney, Joann Labruyere, Madelon T. Price · Science 16 Jun 1989 1,255
40 Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State Eli Samuel Rosenberg, Elizabeth M. Dufort, Tomoko Udo et al. · JAMA Open access 12 May 2020 1,230
41 Cloning of a Delta Opioid Receptor by Functional Expression Christopher J. Evans, Duane E. Keith, Heather Morrison et al. · Science 18 Dec 1992 1,230
42 Endogenous Opioids: Biology and Function Huda Akil, Stanley J. Watson, Elizabeth A. Young et al. · Annual Review of Neuroscience Mar 1984 1,228
43 Anatomy of CNS opioid receptors Alfred Mansour, Henry Khachaturian, Michael Edward Lewis et al. · Trends in Neurosciences Review 1988 1,200
44 A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 Andrea Cortegiani, Giulia Ingoglia, Mariachiara Ippolito et al. · Journal of Critical Care ReviewOpen access 10 Mar 2020 1,190
45 Dynorphin Is a Specific Endogenous Ligand of the κ Opioid Receptor Charles Chavkin, Iain F. James, Avram Goldstein · Science 22 Jan 1982 1,182
46 Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes Uwe Rudolph, Florence Crestani, Dietmar Benke et al. · Nature Oct 1999 1,181
47 G-protein-coupled receptor heterodimerization modulates receptor function Bryen A. Jordan, Lakshmi A. Devi · Nature Open access Jun 1999 1,171
48 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study Lixue Huang et al. · The Lancet Open access Aug 2021 1,149
49 Does Fast Dissociation From the Dopamine D 2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis Shitij Kapur, Philip Seeman · American Journal of Psychiatry Mar 2001 1,135
50 Nitric Oxide Activation of Poly(ADP-Ribose) Synthetase in Neurotoxicity Jie Zhang, Valina L. Dawson, Ted M. Dawson et al. · Science 4 Feb 1994 1,129

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.